To Accelerate Development of Bio Cluster
Incheon Free Economic Zone (IFEZ) Authority announced on Oct. 21 that Commissioner Lee Won-jae visited SCM Lifescience, a company in Songdo International City, on Oct. 20 to explore ways to support biotech venture companies in the Songdo Bio Cluster.
Lee took a tour of research and manufacturing facilities under the guidance of Lee Byung-kun, president of SCM Lifescience, and discussed ways to support collaboration among biotech companies.
SCM Lifescience specializes in cell therapies. It was founded in July 2014 and moved to Songdo in June 2020 to exchange technologies with companies operating in Songdo Bio Cluster and expand research facilities. The company has its own technology in the field of fundamental treatment for immunological diseases and regenerative medicine. It is currently focusing on stem cell-based immunological disease treatments and anti-cancer drugs based on immunocytes.
SCM Lifescience currently has 55 employees and has been growing fast. The company was listed on the KOSDAQ market on June 17. Its major products include stem cell-based treatments for chronic graft-versus-host disease (in phase 2 domestic clinical trial), acute pancreatitis (phase 2 domestic clinical trial), atopy dermatitis (phase 2 domestic clinical trial) and spinocerebellar ataxia or SCA (phase 2 domestic clinical trial) and the acute respiratory distress syndrome. Its products also include anti-cancer drugs based on immunocytes such as a dendritic cell-based anti-cancer vaccine for metastatic kidney cancer (phase 2 clinical trial in the U.S.) and a next-generation CAR-CIK treatment for acute lymphoblastic leukemia (phase 1 clinical trial in Italy).